Your browser doesn't support javascript.
loading
Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn's Disease.
Johnson, Amanda M; Harmsen, William Scott; Aniwan, Satimai; Tremaine, William J; Raffals, Laura E; Abu Dayyeh, Barham K; Loftus, Edward V.
Afiliação
  • Johnson AM; Division of Gastroenterology and Hepatology.
  • Harmsen WS; Biostatistics and Informatics, Mayo Clinic, Rochester, MN.
  • Aniwan S; Division of Gastroenterology and Hepatology.
  • Tremaine WJ; Division of Gastroenterology, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Raffals LE; Division of Gastroenterology and Hepatology.
  • Abu Dayyeh BK; Division of Gastroenterology and Hepatology.
  • Loftus EV; Division of Gastroenterology and Hepatology.
J Clin Gastroenterol ; 2022 Dec 30.
Article em En | MEDLINE | ID: mdl-36728679
ABSTRACT

BACKGROUND:

Obesity is on the rise within the inflammatory bowel disease population. The impact obesity has on the natural history of Crohn's disease (CD) is not well-understood. We aimed to describe the prevalence of obesity in a population-based cohort of newly diagnosed patients with CD, and the impact obesity had on disease phenotype and outcomes of corticosteroid use, hospitalization, intestinal resection, and development of fistulizing or penetrating disease. MATERIALS AND

METHODS:

A chart review was performed on Olmsted County, Minnesota residents diagnosed with CD between 1970 and 2010. Data were collected on demographics, body mass index, CD location and behavior, CD-related hospitalizations, corticosteroid use, and intestinal resection. The proportion of individuals considered obese at the time of CD diagnosis was evaluated over time, and CD-associated complications were assessed with Kaplan-Meier survival analysis.

RESULTS:

We identified 334 individuals diagnosed with CD between 1970 and 2010, of whom 156 (46.7%) were either overweight (27.8%) or obese (18.9%) at the time of diagnosis. The proportion of patients considered obese at the time of their diagnosis of CD increased 2-3 fold over the course of the study period. However, obesity did not have a significant impact on the future risk of corticosteroid use, hospitalization, intestinal resection, or development of penetrating and stricturing complications.

CONCLUSIONS:

Obesity is on the rise in patients with CD, although in this cohort, there did not appear to be any negative association with future CD-related outcomes. Further prospective studies, ideally including obesity measures such as visceral adipose tissue assessment, are warranted to understand the implications of the rising prevalence of obesity on CD outcomes.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article